Display options
Cite
Horikawa Y, Watanabe M, Sadahira T, et al. Overexpression of REIC/Dkk-3 suppresses the expression of CD147 and inhibits the proliferation of human bladder cancer cells. Oncol Lett. 2017;14(3):3223-3228doi: 10.3892/ol.2017.6548.
Horikawa, Y., Watanabe, M., Sadahira, T., Ariyoshi, Y., Kobayashi, Y., Araki, M., Wada, K., Ochiai, K., Li, S. A., & Nasu, Y. (2017). Overexpression of REIC/Dkk-3 suppresses the expression of CD147 and inhibits the proliferation of human bladder cancer cells. Oncology letters, 14(3), 3223-3228. https://doi.org/10.3892/ol.2017.6548
Horikawa, Yuhei, et al. "Overexpression of REIC/Dkk-3 suppresses the expression of CD147 and inhibits the proliferation of human bladder cancer cells." Oncology letters vol. 14,3 (2017): 3223-3228. doi: https://doi.org/10.3892/ol.2017.6548
Horikawa Y, Watanabe M, Sadahira T, Ariyoshi Y, Kobayashi Y, Araki M, Wada K, Ochiai K, Li SA, Nasu Y. Overexpression of REIC/Dkk-3 suppresses the expression of CD147 and inhibits the proliferation of human bladder cancer cells. Oncol Lett. 2017 Sep;14(3):3223-3228. doi: 10.3892/ol.2017.6548. Epub 2017 Jul 08. PMID: 28927069; PMCID: PMC5588074.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2017 Sep;14(3):3223-3228. doi: 10.3892/ol.2017.6548. Epub 2017 Jul 08.

Overexpression of REIC/Dkk-3 suppresses the expression of CD147 and inhibits the proliferation of human bladder cancer cells.

Oncology letters

Yuhei Horikawa, Masami Watanabe, Takuya Sadahira, Yuichi Ariyoshi, Yasuyuki Kobayashi, Motoo Araki, Koichiro Wada, Kazuhiko Ochiai, Shun-Ai Li, Yasutomo Nasu

Affiliations

  1. Department of Urology, Okayama University, Okayama 700-8558, Japan.
  2. Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama 700-8558, Japan.
  3. Department of Veterinary Nursing and Technology, Nippon Veterinary and Life Science University, Musashino, Tokyo 180-8602, Japan.

PMID: 28927069 PMCID: PMC5588074 DOI: 10.3892/ol.2017.6548

Abstract

Our group previously developed an adenoviral vector encoding the REIC/Dkk-3 gene (Ad-REIC), a tumor suppressor, for cancer gene therapy. The Ad-REIC agent induces apoptosis and inhibits invasion in a number of cancer cell lines; however, the molecular mechanisms underlying its effects remain unclear. Cluster of differentiation 147 (CD147), also known as extracellular matrix metalloproteinase inducer (EMMPRIN), is a key molecule that promotes cancer proliferation and invasion. In order to elucidate the therapeutic mechanism of Ad-REIC, its effect on the expression of CD147 in human bladder cancer KK47 cells was investigated. Treatment with Ad-REIC markedly downregulated the expression of CD147 and significantly inhibited cellular proliferation. Since the expression of CD147 is reported to be under the positive control of mitogen-activated protein kinase (MAPK) signaling and the c-Myc protein, the correlations between the expression of CD147 and the activation of MAPKs or the expression of c-Myc were examined. Unexpectedly, no positive correlation was observed between the level of CD147 and the potential regulators that were assessed, indicating that another signaling pathway is responsible for the downregulation of CD147. The results from the present study demonstrate that Ad-REIC treatment can significantly downregulate the expression of CD147 in bladder cancer cells. Downregulation of the cancer-progression factor CD147 may be a novel mechanism that underlies the therapeutic effects of Ad-REIC treatment.

Keywords: CD147; EMMPRIN; REIC/Dkk-3; bladder cancer; cell proliferation

References

  1. Gene. 2002 Jan 9;282(1-2):75-86 - PubMed
  2. Mol Med Rep. 2016 Mar;13(3):2208-14 - PubMed
  3. Cancer Gene Ther. 2016 Nov;23 (11):400-409 - PubMed
  4. Oncotarget. 2015 Sep 22;6(28):24636-48 - PubMed
  5. Cancer Res. 2005 Nov 1;65(21):9617-22 - PubMed
  6. Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16663-8 - PubMed
  7. Int J Oncol. 2015 Nov;47(5):1881-9 - PubMed
  8. Pathol Int. 2006 Jul;56(7):359-67 - PubMed
  9. Biochem Biophys Res Commun. 2008 Sep 26;374(3):517-21 - PubMed
  10. Cancer Res. 2015 Jan 1;75(1):171-80 - PubMed
  11. Int J Oncol. 2012 Jul;41(1):135-40 - PubMed
  12. Oncol Lett. 2014 Mar;7(3):595-601 - PubMed
  13. BJU Int. 2009 Jul;104(2):170-4 - PubMed
  14. Oncoimmunology. 2015 Aug 28;5(2):e1078056 - PubMed
  15. J Hepatol. 2014 Oct;61(4):859-66 - PubMed
  16. Clin Med Insights Oncol. 2015 Mar 23;9:31-8 - PubMed
  17. Biochem Biophys Res Commun. 2008 Sep 12;374(1):111-6 - PubMed
  18. Int J Oncol. 2012 Aug;41(2):559-64 - PubMed
  19. Cancer Res. 2014 Jul 15;74(14):3764-78 - PubMed
  20. Oncol Rep. 2014 Mar;31(3):1089-95 - PubMed
  21. Cell. 2015 May 7;161(4):817-32 - PubMed
  22. J Biochem. 2016 May;159(5):481-90 - PubMed
  23. Cancer Epidemiol. 2010 Aug;34(4):478-82 - PubMed
  24. J Immunol. 2005 Jul 15;175(2):1197-205 - PubMed
  25. Oncotarget. 2016 Feb 23;7(8):9429-47 - PubMed
  26. J Urol. 1992 Aug;148(2 Pt 1):441-5 - PubMed
  27. Acta Med Okayama. 2017 Apr;71(2):135-142 - PubMed
  28. Vascul Pharmacol. 2007 Feb;46(2):114-21 - PubMed
  29. Oncol Lett. 2016 Apr;11(4):2424-2428 - PubMed
  30. Int J Oncol. 2016 Apr;48(4):1650-8 - PubMed
  31. Biomed Res Int. 2015 ;2015 :242437 - PubMed

Publication Types